Skip to main content
SABCS 2023 HR+/HER2-

Real-world Outcomes Following Initiation of Abemaciclib in Patients With Brain Metastases Secondary to HR+/HER2- Metastatic Breast Cancer

Videos - Rapid Reactions
Hope S. Rugo, MD
Professor of Medicine and Winterhof Family Professor of Breast Oncology
University of California San Francisco Comprehensive Cancer Center
San Francisco, CA
Dr Rugo of the University of California San Francisco Comprehensive Cancer Center reports on the outcomes of a retrospective study of patients with metastatic breast cancer and brain metastases treated with abemaciclib.
Related Items
Primary Analysis of HER2CLIMB-02: Addition of Tucatinib to Trastuzumab Emtansine in Previously Treated Patients with HER2-Positive Metastatic Breast Cancer
Sara M. Tolaney, MD, MPH
Videos published on February 8, 2024 in Rapid Reactions
INAVO120 Phase III Study: Treatment of Patients With PIK3CA-mutant, HR+/HER2- Locally Advanced or Metastatic Breast Cancer With Invavolisib in Combination With Palbociclib and Fulvestrant
Hope S. Rugo, MD
Videos published on February 7, 2024 in Rapid Reactions
Abemaciclib and NSAI for 1L Treatment of HR+/HER2- Advanced Breast Cancer: Long-term Survival Data Reported
Sara M. Tolaney, MD, MPH
Videos published on February 6, 2024 in Rapid Reactions